- Home
- LVO vs IMUX Comparison
LVO vs IMUX Comparison
Compare LVO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- IMUX
- Stock Information
- Founded
- LVO 2009
- IMUX 2016
- Country
- LVO United States
- IMUX United States
- Employees
- LVO N/A
- IMUX N/A
- Industry
- LVO Restaurants
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- LVO Consumer Discretionary
- IMUX Health Care
- Exchange
- LVO Nasdaq
- IMUX Nasdaq
- Market Cap
- LVO 72.9M
- IMUX 67.8M
- IPO Year
- LVO N/A
- IMUX N/A
- Fundamental
- Price
- LVO $0.75
- IMUX $0.83
- Analyst Decision
- LVO Strong Buy
- IMUX Strong Buy
- Analyst Count
- LVO 1
- IMUX 6
- Target Price
- LVO $1.50
- IMUX $11.60
- AVG Volume (30 Days)
- LVO 935.9K
- IMUX 1.7M
- Earning Date
- LVO 08-12-2025
- IMUX 08-07-2025
- Dividend Yield
- LVO N/A
- IMUX N/A
- EPS Growth
- LVO N/A
- IMUX N/A
- EPS
- LVO N/A
- IMUX N/A
- Revenue
- LVO $114,405,000.00
- IMUX N/A
- Revenue This Year
- LVO N/A
- IMUX N/A
- Revenue Next Year
- LVO $23.84
- IMUX N/A
- P/E Ratio
- LVO N/A
- IMUX N/A
- Revenue Growth
- LVO N/A
- IMUX N/A
- 52 Week Low
- LVO $0.55
- IMUX $0.56
- 52 Week High
- LVO $1.82
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- LVO 47.15
- IMUX 55.91
- Support Level
- LVO $0.76
- IMUX $0.68
- Resistance Level
- LVO $0.92
- IMUX $0.83
- Average True Range (ATR)
- LVO 0.07
- IMUX 0.05
- MACD
- LVO -0.00
- IMUX 0.02
- Stochastic Oscillator
- LVO 34.78
- IMUX 88.50
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.